US3262977A
(en)
*
|
1962-03-10 |
1966-07-26 |
Chinoin Gyogyszer Es Vegyeszet |
N-aralkyl-1, 1-diphenyl-propylamine derivatives
|
NL296693A
(en)
*
|
1962-08-16 |
|
|
|
FR95908E
(en)
*
|
1963-11-09 |
1972-01-31 |
Degussa |
Process for the preparation of novel aminoketones and corresponding secondary alcohols.
|
US3457354A
(en)
*
|
1965-09-21 |
1969-07-22 |
Merck & Co Inc |
Treatment of hypertension with 2-hydroxy (or amino) - 4,5 - dihydroxyphenethylamine derivatives
|
US3895057A
(en)
*
|
1967-10-13 |
1975-07-15 |
Dainippon Pharmaceutical Co |
Aminoalkanols and their pharmaceutically acceptable acid-addition salts, and production thereof
|
US4329367A
(en)
*
|
1974-08-05 |
1982-05-11 |
Ciba-Geigy Corporation |
1-(Aralkoxyphenyl)-2-(bis-arylalkylamino)-alkanes
|
DE2902172C2
(en)
*
|
1979-01-20 |
1984-05-10 |
UOP Inc., 60016 Des Plaines, Ill. |
Process for the preparation of an N, N'-dialkylphenylenediamine
|
EP0198412B1
(en)
*
|
1985-04-16 |
1989-03-22 |
F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft |
Phenethanol amine derivatives
|
US6982251B2
(en)
*
|
2000-12-20 |
2006-01-03 |
Schering Corporation |
Substituted 2-azetidinones useful as hypocholesterolemic agents
|
CN100522159C
(en)
*
|
2001-01-26 |
2009-08-05 |
先灵公司 |
The use of substituted azetidinone compounds for the treatment of sitosterolemia
|
EP1353695A2
(en)
*
|
2001-01-26 |
2003-10-22 |
Schering Corporation |
Combinations of nicotinic acid and derivatives thereof and sterol absorption inhibitor(s) and treatments for vascular indications
|
RS20100015A
(en)
*
|
2001-01-26 |
2010-12-31 |
Schering Corporation |
Combination of receptor activator activated by fenofibrate peroxisome-proliferator (ppar) with sterol absorption inhibitor ezetimibe for vascular indications
|
ES2296894T3
(en)
*
|
2001-01-26 |
2008-05-01 |
Schering Corporation |
COMBINATIONS OF EZETIMIBA WITH ASPIRINE TO TREAT VASCULAR STATES.
|
DK1385548T3
(en)
*
|
2001-01-26 |
2007-09-10 |
Schering Corp |
Combinations of sterol absorption inhibitor (s) with cardiovascular (s) for the treatment of vascular conditions
|
WO2002058733A2
(en)
*
|
2001-01-26 |
2002-08-01 |
Schering Corporation |
Combinations of bile acid sequestrant(s) and sterol absorption inhibitor(s) and treatments for vascular indications
|
US7071181B2
(en)
*
|
2001-01-26 |
2006-07-04 |
Schering Corporation |
Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
|
CA2447884A1
(en)
*
|
2001-05-25 |
2002-12-05 |
Schering Corporation |
Use of azetidinone substituted derivatives in the treatment of alzheimer's disease
|
MXPA04002572A
(en)
*
|
2001-09-21 |
2004-05-31 |
Schering Corp |
Methods for treating or preventing vascular inflammation using sterol absorption inhibitor(s).
|
US20030119808A1
(en)
*
|
2001-09-21 |
2003-06-26 |
Schering Corporation |
Methods of treating or preventing cardiovascular conditions while preventing or minimizing muscular degeneration side effects
|
WO2003026643A2
(en)
*
|
2001-09-21 |
2003-04-03 |
Schering Corporation |
Treatment of xanthoma with azetidinone derivatives as sterol absorption inhibitors
|
US7053080B2
(en)
*
|
2001-09-21 |
2006-05-30 |
Schering Corporation |
Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
|
US7056906B2
(en)
*
|
2001-09-21 |
2006-06-06 |
Schering Corporation |
Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
|
OA12905A
(en)
|
2002-08-19 |
2006-10-13 |
Pfizer Prod Inc |
Combination therapy for hyperproliferative diseases.
|
EP1560579A1
(en)
*
|
2002-11-06 |
2005-08-10 |
Schering Corporation |
Cholesterol absorption inhibitors for the treatment of autoimmune disorders
|
EP1606287B1
(en)
*
|
2003-03-07 |
2013-10-02 |
Merck Sharp & Dohme Corp. |
Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia
|
MXPA05009503A
(en)
|
2003-03-07 |
2005-10-18 |
Schering Corp |
Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia.
|
US7459442B2
(en)
|
2003-03-07 |
2008-12-02 |
Schering Corporation |
Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
|
DE602004018617D1
(en)
|
2003-03-07 |
2009-02-05 |
Schering Corp |
SUBSTITUTED AZETIDINONE DERIVATIVES, THEIR PHARMACEUTICAL FORMULATIONS AND THEIR USE FOR THE TREATMENT OF HYPERCHOLESTEROLMIA
|
JP2007510659A
(en)
*
|
2003-11-05 |
2007-04-26 |
シェーリング コーポレイション |
Combinations of lipid modulators and substituted azetidinones and treatment of vascular conditions
|
MX2007000979A
(en)
*
|
2004-07-26 |
2007-07-11 |
Cotherix Inc |
Treatment of pulmonary hypertension by inhaled iloprost with a microparticle formulation.
|
US20060063803A1
(en)
*
|
2004-09-23 |
2006-03-23 |
Pfizer Inc |
4-Amino substituted-2-substituted-1,2,3,4-tetrahydroquinoline compounds
|
US7741317B2
(en)
|
2005-10-21 |
2010-06-22 |
Bristol-Myers Squibb Company |
LXR modulators
|
EP2351569B1
(en)
|
2005-10-26 |
2012-08-22 |
Asahi Kasei Pharma Corporation |
Fasudil in combination therapies for the treatment of pulmonary arterial hypertension
|
WO2007050783A2
(en)
|
2005-10-26 |
2007-05-03 |
Asahi Kasei Pharma Corporation |
Fasudil in combination therapies for the treatment of pulmonary arterial hypertension
|
US7888376B2
(en)
|
2005-11-23 |
2011-02-15 |
Bristol-Myers Squibb Company |
Heterocyclic CETP inhibitors
|
US7919506B2
(en)
|
2006-03-10 |
2011-04-05 |
Pfizer Inc. |
Dibenzyl amine compounds and derivatives
|
WO2008070496A2
(en)
|
2006-12-01 |
2008-06-12 |
Bristol-Myers Squibb Company |
N- ( (3-benzyl) -2, 2- (bis-phenyl) -propan-1-amine derivatives as cetp inhibitors for the treatment of atherosclerosis and cardiovascular diseases
|
US8969514B2
(en)
|
2007-06-04 |
2015-03-03 |
Synergy Pharmaceuticals, Inc. |
Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
|
US20100120694A1
(en)
|
2008-06-04 |
2010-05-13 |
Synergy Pharmaceuticals, Inc. |
Agonists of Guanylate Cyclase Useful for the Treatment of Gastrointestinal Disorders, Inflammation, Cancer and Other Disorders
|
US7879802B2
(en)
|
2007-06-04 |
2011-02-01 |
Synergy Pharmaceuticals Inc. |
Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
|
ES2624828T3
(en)
|
2008-07-16 |
2017-07-17 |
Synergy Pharmaceuticals Inc. |
Guanylate cyclase agonists useful for the treatment of gastrointestinal disorders, inflammation, cancer and others
|
US9616097B2
(en)
|
2010-09-15 |
2017-04-11 |
Synergy Pharmaceuticals, Inc. |
Formulations of guanylate cyclase C agonists and methods of use
|
WO2012037665A1
(en)
|
2010-09-24 |
2012-03-29 |
Oral Delivery Technology Ltd. |
Nitric oxide releasing amino acid ester for treatment of pulmonary hypertension and other respiratory conditions
|
CA2905438A1
(en)
|
2013-03-15 |
2014-09-25 |
Synergy Pharmaceuticals Inc. |
Agonists of guanylate cyclase and their uses
|
AU2014235209B2
(en)
|
2013-03-15 |
2018-06-14 |
Bausch Health Ireland Limited |
Guanylate cyclase receptor agonists combined with other drugs
|
RU2618628C1
(en)
|
2013-04-17 |
2017-05-05 |
Пфайзер Инк. |
N-piperidin-3-yl-benzamide derivatives for cardiovascular diseases treatment
|
EP3004138B1
(en)
|
2013-06-05 |
2024-03-13 |
Bausch Health Ireland Limited |
Ultra-pure agonists of guanylate cyclase c, method of making and using same
|
WO2016055901A1
(en)
|
2014-10-08 |
2016-04-14 |
Pfizer Inc. |
Substituted amide compounds
|
CA3125765A1
(en)
|
2019-01-18 |
2020-07-23 |
Astrazeneca Ab |
Pcsk9 inhibitors and methods of use thereof
|